Intuitive Surgical (NASDAQ:ISRG) Director Amy Ladd Sells 72 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amy Ladd sold 72 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total transaction of $28,303.20. Following the transaction, the director directly owned 179 shares of the company’s stock, valued at approximately $70,364.90. This trade represents a 28.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Stock Up 2.0%

Shares of ISRG stock opened at $401.23 on Wednesday. The stock has a fifty day moving average of $392.47 and a 200 day moving average of $443.35. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The firm has a market capitalization of $141.75 billion, a price-to-earnings ratio of 45.96, a PEG ratio of 2.84 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.48 by $0.32. The company had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. Intuitive Surgical’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 earnings per share. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Key Headlines Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical’s second-quarter results exceeded expectations: revenue rose 18.4% year over year to $2.89 billion, while EPS reached $2.80 versus the $2.48 consensus estimate. Higher margins, continued adoption of its da Vinci and Ion platforms, and long-term demand for robotic-assisted surgery support the bullish case. Intuitive Surgical Just Beat Earnings
• Positive Sentiment: A bullish investor cited Intuitive Surgical’s potential once-per-decade hardware replacement cycle and approximately $8.6 billion cash position, arguing that the more than 30% year-to-date decline could create an attractive long-term entry point. The Number One Reason I Keep Buying Intuitive Surgical
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a “Moderate Buy” consensus and an average price target of $509.02. However, several firms recently lowered their targets, reflecting greater caution after the earnings report.
• Neutral Sentiment: Reported short interest was zero shares, implying no measurable short-selling pressure. The figure appears unusual and may reflect incomplete or unreliable data rather than a meaningful market signal.
• Negative Sentiment: Despite the earnings beat, investors remain concerned about slowing domestic procedure growth and whether the company’s roughly 46 P/E adequately reflects its growth prospects. Those concerns have contributed to the stock’s recent weakness. Intuitive Surgical Earnings and Valuation Analysis
• Negative Sentiment: Director Amy L. Ladd sold 472 shares across August 10–11, reducing her holdings by a substantial percentage, while EVP Gary Loeb sold 400 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their significance as a discretionary bearish signal but may still weigh modestly on sentiment.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ISRG shares. BNP Paribas Exane upgraded Intuitive Surgical to an “outperform” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group set a $558.00 price objective on Intuitive Surgical in a research report on Wednesday, May 27th. Wells Fargo & Company restated an “overweight” rating and set a $487.00 target price (down from $654.00) on shares of Intuitive Surgical in a report on Friday, July 17th. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Tuesday, May 19th. Finally, Robert W. Baird decreased their price target on shares of Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $509.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ISRG. Laurel Wealth Advisors LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $31,000. Turning Point Benefit Group Inc. boosted its position in shares of Intuitive Surgical by 833.3% during the fourth quarter. Turning Point Benefit Group Inc. now owns 56 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 50 shares during the last quarter. Motiv8 Investments LLC bought a new stake in Intuitive Surgical in the 4th quarter worth about $34,000. Oakworth Capital Inc. raised its position in Intuitive Surgical by 281.2% in the 4th quarter. Oakworth Capital Inc. now owns 61 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 45 shares during the last quarter. Finally, Main Street Group LTD purchased a new position in Intuitive Surgical in the 1st quarter worth about $30,000. Institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.